Ticker League

Alnylam Pharmaceuticals (ALNY) Income Statement Waterfall

Follow every dollar of Alnylam Pharmaceuticals's revenue down to net income — how much COGS, OpEx, and taxes each consume, and the margin that survives at every step.

TTM

Revenue

$4.29B

Gross Margin

+80.9%

Operating Margin

+17.5%

Net Margin

+13.5%

Income statement waterfall for Alnylam Pharmaceuticals (ALNY) — TTM through Q1 2026

Net income: $577.22M

Margin breakdown for Alnylam Pharmaceuticals (ALNY) — TTM through Q1 2026

  • Revenue$4.29B
  • Cost of Revenue−$819.03M
  • Gross Profit$3.47B
  • Operating Expenses−$2.72B
  • Operating Income$752.14M
  • Other Income / Expense−$165.74M
  • Pre-tax Income$586.40M
  • Tax Benefit$22.14M
  • Other Items−$31.32M
  • Net Income$577.22M
Want to see what changed vs last year?Profit Bridge

Frequently asked questions

Data & methodology

Explore more

Deep-dives across the income statement, cash flow, capital return, and valuation